Analytical Data
-
基因名
SLC22A12
- Application
-
别名
SLC22A12; OAT4L; RST; Solute Carrier Family 22 Member 12,Organic Anion/Urate Transporter; Organic anion transporter 4-like; Urate anion exchanger 1; Renal-specific transporter
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q96S37
-
表达区间
Glu281~Thr350
-
分子量
12kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC22A12, also known as urate transporter 1 (URAT1), is a member of the solute carrier family, primarily responsible for the reabsorption of uric acid in the kidneys. Dysregulation of SLC22A12 has been implicated in various diseases, particularly gout and hyperuricemia, making it a crucial target for therapeutic interventions. Given this biological significance, the study of SLC22A12 recombinant protein has gained momentum in recent years. Researchers are focused on characterizing its structure, function, and role in uric acid homeostasis. Recombinant SLC22A12 can be produced using various expression systems, allowing for detailed studies of its transport mechanisms and interactions with uric acid as well as other potential substrates. High-throughput screening of small molecules that can modulate SLC22A12 activity may lead to novel treatments for conditions associated with elevated uric acid levels. Furthermore, understanding polymorphisms within the SLC22A12 gene can provide insights into individual variations in uric acid metabolism, paving the way for personalized medicine approaches. Overall, the investigation of SLC22A12 recombinant protein is a promising area of research that holds potential for advancing our understanding of renal transport processes and developing new strategies for managing hyperuricemic disorders.
